Literature DB >> 18171418

Expression profiling technology: its contribution to our understanding of breast cancer.

E A Rakha1, M E El-Sayed, J S Reis-Filho, I O Ellis.   

Abstract

Breast cancer is a complex genetic disease characterized by the accumulation of multiple molecular alterations. Routine clinical management of breast cancer relies on clinical and pathological factors, however. These seem insufficient to reflect the whole clinical heterogeneity of tumours and are less than perfectly adapted to each patient. Recent advances in human genome research and high-throughput molecular technologies have made it possible to tackle the molecular complexity of breast cancer and have contributed to the realization that the biological heterogeneity of breast cancer has implications for treatment. Gene expression profiling of breast cancer has been performed using several approaches. This review will describe the details of gene expression profiling of breast cancer, the different approaches and the impact on clinical management.

Entities:  

Mesh:

Year:  2008        PMID: 18171418     DOI: 10.1111/j.1365-2559.2007.02894.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  10 in total

Review 1.  Gene signature of the metastatic potential of cutaneous melanoma: too much for too little?

Authors:  József Tímár; Balázs Gyorffy; Erzsébet Rásó
Journal:  Clin Exp Metastasis       Date:  2010-02-24       Impact factor: 5.150

2.  Predictive and prognostic molecular markers for cancer medicine.

Authors:  Sunali Mehta; Andrew Shelling; Anita Muthukaruppan; Annette Lasham; Cherie Blenkiron; George Laking; Cristin Print
Journal:  Ther Adv Med Oncol       Date:  2010-03       Impact factor: 8.168

3.  The Immunohistochemical Expression of the Oestrogen Receptor (ER), HER-2/NEU and Cytokeratin 8/18 and 5/6 in Invasive Breast Carcinoma.

Authors:  Bharti Rattan; Mridu Manjari; S K Kahlon; Nikita Kalra; Amarpreet Bhalla; Surinder Paul
Journal:  J Clin Diagn Res       Date:  2012-11

4.  The majority of triple-negative breast cancer may correspond to basal-like carcinoma, but triple-negative breast cancer is not identical to basal-like carcinoma.

Authors:  Naoto Kuroda; Masahiko Ohara; Kaori Inoue; Keiko Mizuno; Nokiaki Fujishima; Nobumasa Hamaguchi; Gang-Hong Lee
Journal:  Med Mol Morphol       Date:  2009-06-18       Impact factor: 2.309

5.  Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review).

Authors:  Mei Hong Zhang; Hong Tao Man; Xiao Dan Zhao; Ni Dong; Shi Liang Ma
Journal:  Biomed Rep       Date:  2013-10-25

6.  p16 expression correlates with basal-like triple-negative breast carcinoma.

Authors:  Amany A Abou-Bakr; Hany I Eldweny
Journal:  Ecancermedicalscience       Date:  2013-05-14

7.  Genotyping analysis and ¹⁸FDG uptake in breast cancer patients: a preliminary research.

Authors:  Valentina Bravatà; Alessandro Stefano; Francesco P Cammarata; Luigi Minafra; Giorgio Russo; Stefania Nicolosi; Sabina Pulizzi; Cecilia Gelfi; Maria C Gilardi; Cristina Messa
Journal:  J Exp Clin Cancer Res       Date:  2013-04-30

8.  Gene expression variation between distinct areas of breast cancer measured from paraffin-embedded tissue cores.

Authors:  Martina Schobesberger; Anna Baltzer; Andrea Oberli; Andreas Kappeler; Mathias Gugger; Hana Burger; Rolf Jaggi
Journal:  BMC Cancer       Date:  2008-11-25       Impact factor: 4.430

9.  Pituitary tumor-transforming gene 1 is expressed in primary ductal breast carcinoma, lymph node infiltration, and distant metastases.

Authors:  Fabio Grizzi; Sonia Di Biccari; Barbara Fiamengo; Sanja Štifter; Piergiuseppe Colombo
Journal:  Dis Markers       Date:  2013       Impact factor: 3.434

10.  Clinicopathologic features of triple negative breast cancers: an experience from Pakistan.

Authors:  Atif Ali Hashmi; Muhammad Muzzammil Edhi; Hanna Naqvi; Naveen Faridi; Amna Khurshid; Mehmood Khan
Journal:  Diagn Pathol       Date:  2014-02-28       Impact factor: 2.644

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.